Zydus Lifesciences Ltd
NSE: ZYDUSLIFE · Pharmaceuticals · sector
₹1,160.40NSE close 2026-10-26
Key numbers
Market cap₹1,15,808 cr
Price₹1,160.40
52w high / low₹1,232 / ₹836
P/E25.9xSector median 27.9x
P/B4.3xSector median 2.9x
Book value₹271.7
Dividend yield0.95%Sector median 0.48%
ROE17.7%Sector median 11.7%
ROCE16.8%Sector median 12.3%
OPM27.2%Sector median 14.0%
Debt / equity0.43xSector median 0.16x
EV/EBITDA15.5xSector median 18.6x
Interest cover12.8x
Current ratio1.27x
Sales growth 3y+16.4%Sector median +9.6%
Profit growth 3y+37.0%Sector median +13.3%
PEG0.70x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹7,192 cr vs borrowings ₹11,770 cr (FY26): borrowings are higher by ₹4,577 cr.
- Operating profit covered interest 12.8x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 2 of the last 5 years (FY26, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 10% of net profit in the last 12 months.
- Debtor days went from 97 (FY24) to 73 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹1,160.40 on 2026-10-26: -5.8% from the 52-week high, +38.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,205.00 · low ₹844.40
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 |
| EBITDA | 1,461 | 1,388 | 1,906 | 2,088 | 1,982 | 1,732 | 2,157 | 1,911 |
| OPM % | 27.9% | 26.3% | 29.2% | 31.8% | 32.4% | 25.2% | 28.4% | 23.8% |
| Other income | 68 | 58 | 81 | 155 | 109 | 111 | 134 | 106 |
| Net profit | 911 | 1,024 | 73 | 1,467 | 1,259 | 1,042 | 1,272 | 940 |
| EPS (₹) | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.35 |
| Revenue YoY | +16.9% | +30.3% | +16.2% | +22.0% | ||||
| Profit YoY | +38.1% | +1.8% | +1,647.9% | -35.9% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 | 28,592 |
| EBITDA | 3,453 | 3,256 | 5,370 | 6,839 | 7,958 | 7,781 |
| Net profit | 4,487 | 1,960 | 113 | 147 | 5,040 | 4,513 |
| EPS (₹) | 43.84 | 19.30 | 38.14 | 44.97 | 50.09 | 44.87 |
| Revenue growth | +12.9% | +13.4% | +18.9% | +16.8% | +21.1% | |
| Profit growth | -56.3% | -94.2% | +29.8% | +3,326.2% | +29.9% | |
| Dividend / share (₹) | 3.50 | 2.50 | 6.00 | 3.00 | 11.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +16.3% | +12.4% | +21.1% |
| Net profit | +37.0% | +18.8% | +29.9% |
| EPS | +37.4% | +19.2% | – |
| Share price | – | +5.4% (2y) | +11.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 17,516 | 19,830 | 23,953 | 27,111 |
| Borrowings | – | 1,163 | 769 | 3,170 | 11,770 |
| Cash & equivalents | – | 1,192 | 1,358 | 7,808 | 7,192 |
| Total assets | – | 25,756 | 29,281 | 37,202 | 52,407 |
| Fixed assets | – | 5,696 | 5,803 | 6,042 | 9,231 |
| Capital work in progress | – | 1,130 | 1,112 | 1,318 | 1,166 |
| Investments | – | 511 | 552 | 414 | 598 |
| Receivables | – | 4,417 | 5,220 | 4,025 | 5,416 |
| Inventory | – | 3,413 | 3,442 | 3,944 | 5,628 |
| Payables | – | 2,125 | 2,127 | 2,306 | 2,845 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 2,078 | 2,689 | 3,228 | 6,777 | 2,117 |
| Cash from investing | 1,154 | 1,171 | -1,475 | -8,372 | -8,296 |
| Cash from financing | -868 | -4,400 | -1,804 | 2,031 | 5,997 |
| Capex | 1,203 | 1,031 | 907 | 1,713 | 3,394 |
| Free cash flow | 876 | 1,658 | 2,321 | 5,064 | -1,277 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 11.2% | 0.6% | 0.6% | 18.6% |
| ROCE % | – | 14.6% | 23.7% | 22.8% | 18.2% |
| Debtor days | – | 94 | 97 | 63 | 73 |
| Inventory days | – | 197 | 202 | 227 | 282 |
| Payable days | – | 123 | 125 | 133 | 142 |
| Cash conversion cycle (days) | – | 168 | 174 | 157 | 213 |
| Working capital days | – | 95 | 114 | 126 | 56 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 75.01% |
| FIIs | 7.05% |
| DIIs | 11.28% |
| of which Mutual funds | 6.88% |
| of which Insurance | 4.20% |
| Government | 0.00% |
| Public (non-institutions) | 6.66% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 74.99% | 74.99% | 74.99% | 75.00% | 75.00% | 75.01% | 75.01% | 75.01% |
| Promoter group | % |
|---|---|
| Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees) | 74.98% |
| Arati Rajiv Mehta | 0.01% |
| Pankaj Ramanbhai Patel | 0.00% |
| Pankaj Ramanbhai Patel HUF (Pankaj Ramanbhai Patel-Karta) | 0.00% |
| Pritiben Pankajbhai Patel | 0.00% |
| Sharvil Pankajbhai Patel | 0.00% |
| Shivani Pankajbhai Patel | 0.00% |
| Ayushi Rajiv Mehta jointly with Arati Rajiv Mehta | 0.00% |
| Ritaben Yatinbhai Desai | 0.00% |
| Gira Vijay Patel | 0.00% |
| Meha Sharvil Patel | 0.00% |
| Shaurya Sharvil Patel | 0.00% |
| Veda Sharvil Patel | 0.00% |
| Kektiben Mukeshbhai Patel | 0.00% |
| Sharvil P. Patel HUF | 0.00% |
| Public holders above 1% | % |
|---|---|
| Life Insurance Corporation Of India | 3.77% |
| Parag Parikh Flexi Cap Fund | 2.01% |
| Quant Mutual Fund - Quant Multi Cap Fund | 1.49% |
| Kotak Flexicap Fund | 1.07% |
3,82,067 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LUPIN | ₹89,616 cr | 16.2x | 4.0x | 27.9% | 27.9% | 30.0% | +18.9% | 0.61% |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Pharmaceuticals | ₹22,412 cr | 82.6% | ₹7,049 cr | 31.5% |
| Consumer products | ₹3,954 cr | 14.6% | ₹267 cr | 6.8% |
| Medical technologies | ₹782 cr | 2.9% | ₹-178 cr | -22.8% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-24 | Dividend | Dividend - Re 1 Per Share |
| 2026-05-29 | Buyback | Buy Back |
| 2025-07-25 | Dividend | Dividend - Rs 11 Per Share |
| 2024-07-26 | Dividend | Dividend - Rs 3 Per Share |
| 2024-02-23 | Buyback | Buy Back |
| 2023-07-28 | Dividend | Dividend - Rs 6 Per Share |
| 2022-07-28 | Dividend | Dividend - Rs 2.50 Per Share |
| 2022-06-01 | Buyback | Buyback |
| 2021-07-28 | Dividend | Annual General Meeting/Dividend - Rs 3.50 Per Share |
| 2020-08-12 | Other | Annual General Meeting |
| 2020-03-23 | Dividend | Interim Dividend - Rs 3.50 Per Share |
| 2019-07-25 | Dividend | Annual General Meeting/Dividend - Rs 3.50 Per Share |
| 2018-07-31 | Dividend | Annual General Meeting/Dividend- Rs 3.50 Per Share (Purpose Revised) |
| 2017-07-27 | Other | Annual General Meeting |
| 2017-03-16 | Dividend | Interim Dividend Rs 3.20 Per Share (Purpose Revised) |
| 2016-07-21 | Other | Annual General Meeting |
| 2016-03-17 | Dividend | Interim Dividend - Rs 3.20/- Per Share |
| 2015-10-06 | Split | Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share |
| 2015-07-30 | Dividend | Annual General Meeting/Dividend - Rs 12/- Per Share |
| 2014-07-17 | Dividend | Annual General Meeting / Dividend - Rs 9/- Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals: Research and development, manufacturing, marketing, and distribution of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage formulations
- Consumer Wellness: Research and development, manufacturing, marketing and distribution of consumer health and wellness products
- Medical Devices: Research and development, precision manufacturing, clinical collaboration, and global distribution of advanced medical technologies, including cardiovascular intervention devices, diagnostic solutions, and patientcentric healthcare innovations
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ZYDUSLIFE |
| BSE code | 532321 |
| ISIN | INE010B01027 |
| Face value | ₹1.0 |
| Incorporated | 1995-05-15 |
| Website | www.zyduslife.com |
| Plants (India / abroad) | 38 / 6 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.